Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126183271 | 12618327 | 1 | I | 20160725 | 20160803 | 20160803 | EXP | FR-NOVOPROD-503636 | NOVO NORDISK | 0.00 | F | Y | 0.00000 | 20160803 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126183271 | 12618327 | 1 | PS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 0.6 MG, QD | UNKNOWN | 22341 | .6 | MG | SOLUTION FOR INJECTION | QD | |||||
| 126183271 | 12618327 | 2 | C | WYSTAMM | RUPATADINE FUMARATE | 1 | UNK | 0 | |||||||||||
| 126183271 | 12618327 | 3 | C | GLITAZONE | 2 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126183271 | 12618327 | 1 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126183271 | 12618327 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126183271 | 12618327 | Abdominal pain upper | |
| 126183271 | 12618327 | Asthenia | |
| 126183271 | 12618327 | Blood glucose decreased | |
| 126183271 | 12618327 | Constipation | |
| 126183271 | 12618327 | Decreased appetite | |
| 126183271 | 12618327 | Impaired gastric emptying | |
| 126183271 | 12618327 | Nausea | |
| 126183271 | 12618327 | Somnolence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |